*February 2022*
Acquired Resistance to EGFR TKIs, Dr. Katerina Politi, presenter
Histological transformation and off target mechanisms are frequently identified on disease progression for patients with EGFRmutant lung cancer treated with first-line osimertinib, Dr. Noura Choudhury, presenter
What Is the Current and Future Role of IO in EGFR and Other Driver Mutation-Positive NSCLC? Dr. Jonathan Riess, presenter
Investigating Osimertinib Efficacy in Patients with Tumors Harboring the Uncommon EGFR Exon Deletion 19 Mutation L747-A750>P, Dr. Michael Grant, presenter